The Cigna Group CI
Composite 55/100; the shares have moved about 28% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 38/100 — a slight mark against it.
Valuation ranks 82/100 — a strong point in its favour. Growth ranks 63/100 — a moderate point in its favour. Income ranks 63/100 — a moderate point in its favour.
Balance-sheet strength ranks 38/100 — a slight mark against it. Momentum ranks 45/100 — a slight mark against it. Quality ranks 45/100 — a slight mark against it.
What the company does The Cigna Group operates through Evernorth Health Services (pharmacy and specialty care) and Cigna Healthcare (U.S. and international medical plans), offering integrated health benefits, pharmacy management, and global solutions.
Key financials Cigna’s profitability metrics include ROE 16.8%, ROA 4.5%, gross/operating/net margins of 9.1%/4.0%/2.3%, revenue growth 6.7%, and EPS growth 10.2%. Leverage stands at Debt/Equity 0.74 and Net debt/EBITDA 1.93, with a current ratio of 0.85.
Stock health Momentum is mixed: +6.96% over 12 months but -8.93% below the 52-week high, with RSI(14) at 48.30. Income yield is 2.2% (payout ratio 25.4%), and FCF yield is 10.7%. Sideravia scores Quality 39.3 and Valuation 88.6.
Price vs fair value The stock trades at a discount of 20.90% versus the analyst mean target of 341.42. - Jefferies downgraded Cigna to Hold citing 2027 earnings headwinds (Investing.com) - Recent earnings beat and guidance hikes for peers contrast with Cigna’s muted reaction (Barrons.com) - Sector rotation away from healthcare names may weigh on sentiment (Barrons.com)
Looking forward Forward P/E of 9.03 and PEG of 0.38 suggest valuation support, but weak Quality and Growth scores (39.3 and 50.4) highlight execution risks. Analysts cite 2027 headwinds, balancing discounted pricing with operational challenges.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.